Shots:

• The P-III study involves assessing of BAT1706 vs EU Avastin (bevacizumab) + chemotherapy in patients with non-squamous NSCLC- evaluating its safety- efficacy- PK & immunogenicity
• The trial resulted in meeting its 1EPs and demonstrated the equivalence in ORR for 1L patients with advanced non-squamous NSCLC
• BAT1706 is mAb & second biosimilar in Bio-Thera’s portfolio works as a vascular endothelial growth factor (VEGF) protein. Avastin is a mAb targeted to treat patients with metastatic colorectal cancer- non-squamous NSCLC- recurrent glioblastoma- metastatic RCC- persistent- recurrent- or metastatic CC- and epithelial ovarian- fallopian tube- or primary peritoneal cancer

Click here to read full press release/ article | Ref: Businesswire | Image: Twitter